Patents Examined by Shirley V. Gembeh
  • Patent number: 12011437
    Abstract: An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.
    Type: Grant
    Filed: March 6, 2024
    Date of Patent: June 18, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David Osborne
  • Patent number: 12011457
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: June 18, 2024
    Assignee: AZURA OPHTHALMICS LTD
    Inventors: Doron Friedman, Yair Alster, Omer Rafaeli, Shimon Amselem, Zakhar Nudelman
  • Patent number: 12005145
    Abstract: A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. The temperature of the particles does not exceed 35° C. This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: June 11, 2024
    Assignee: Applied Materials, Inc.
    Inventors: Colin C. Neikirk, Jonathan Frankel
  • Patent number: 11998654
    Abstract: A biocompatible material for securing such implantable medical devices, for example by using an adhesive path.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: June 4, 2024
    Assignee: Bard Shannon Limited
    Inventors: Gideon Sturlesi, Guy Tomer, Aurelie Benaddi, Mary Hainrichson, Amir Hadid, Ofer Yatziv
  • Patent number: 11992577
    Abstract: The present disclosure provides medical products including an adhesive containing a carboxyalkyl cellulose and sorbitol. Such medical products can find use as a bolster material for use in conjunction with a surgical fastening device such as a stapler. Such adhesives may include advantageous properties such as the ability to retain tack while stored under a peelable cover. Related methods of manufacture and use are also described.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: May 28, 2024
    Assignee: Cook Biotech Incorporated
    Inventors: Loran Solorio, Steven Cohen, Benjamin Patrick Kline
  • Patent number: 11992480
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: May 28, 2024
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David W. Osborne, Howard Welgus
  • Patent number: 11992556
    Abstract: This invention relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. The aerosol composition comprises ciclesonide, ethanol and either 1, 1, 1, 2-tetrafluoroethane, or 1, 1, 1, 2, 3, 3, 3-heptafluoropropane.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: May 28, 2024
    Assignee: Covis Pharma GmbH
    Inventors: Helgert Müller, Renate Engelstätter, Ulrich Bildmann, Andrea Bauer, Paul McGlynn
  • Patent number: 11992501
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: May 28, 2024
    Assignee: Renosis, Inc.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 11986003
    Abstract: A synthetic nutritional composition comprising a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential, and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: May 21, 2024
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Nora Schneider, Jonas Hauser, Sean Deoni, Tamas Bartfai, Jonathan O'Regan
  • Patent number: 11986446
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: May 21, 2024
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Patent number: 11985999
    Abstract: A method of improving flavor of a combination of a composition for increasing circulating ketone levels is disclosed. A composition containing (D)-?-hydroxybutyric acid (D-BHB), (D)-?-hydroxyvaleric acid (D-BHV), and (D)-1,3 butanediol (D-1,3BD) is disclosed. Exemplary compositions may be incorporated into food, supplement, and beverage products.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: May 21, 2024
    Assignee: VITANAV, INC.
    Inventors: Devon Price, Peter Bayne
  • Patent number: 11987404
    Abstract: The present invention regards a method for filling containers with a single-dose composition comprising or, alternatively, consisting of mannitol in powder form. Such process comprises the following steps: a) breaking up a coherent mass of powder mannitol, so as to obtain a broken-up mass from said coherent mass; c) filling a plurality of containers with the broken-up mass of step a), wherein a bulk density of the coherent mass is smaller than a bulk density of the broken-up mass.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: May 21, 2024
    Assignee: NTC S.R.L.
    Inventors: Luciano Marcelloni, Federico Bertocchi
  • Patent number: 11980691
    Abstract: Enteric softgel capsules comprise a fill material and an enteric shell composition, characterized in that the enteric nature of the capsules may be achieved without an enteric coating or added conventional enteric polymers.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: May 14, 2024
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Toshikazu Okayama, Miyako Takahashi, Takuma Fujii
  • Patent number: 11980596
    Abstract: The present invention provides devices and methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: May 14, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jingli Wang, Michael Cannamela, Hong Yan, Rochelle Kleinberg
  • Patent number: 11976300
    Abstract: Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: May 7, 2024
    Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Haiyan Xu, Jian Liu, Tao Wang, Bing Han, Jie Meng, Tao Wen
  • Patent number: 11975092
    Abstract: The instant disclosure relates to hair treatment compositions that include a unique combination of components that function to impart desirable cosmetic properties to the hair. The hair treatment compositions typically include: at least 0.5 wt. % of at least one non-polymeric mono, di, or tricarboxylic acid, and/or a salt thereof; one or more amines selected from the group consisting of diamines, polyamines, alkylamines, alkanolamines, and a mixture thereof; one or more fructan polysaccharides; one or more prosolvents; and water.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: May 7, 2024
    Assignee: L'OREAL
    Inventors: Barbara Mitchell, Anand Ramchandra Mahadeshwar, Jacob Gordon
  • Patent number: 11969442
    Abstract: Covid-19 binding aerosols are provided. The Covid-19 binding aerosols include Fe3O4 microparticles, at least one organoselenium compound, at least one essential oil, and incense. The Covid-19 binding aerosols may be formulated for use in any product that is capable of emitting aerosols, including but not limited to as air fresheners, as incense, or the like. The Fe3O4 microparticles may have an average size of 5,000 nm-10,000 nm (between 5-10 ?m). The Covid-19 binding aerosols are formulated as aerosol compositions having an average size of greater than 60 ?m-100 ?m to ensure effective binding to virions.
    Type: Grant
    Filed: July 7, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Saadeldin Elsayed Ibrahim Shabaan, Jihad Wadai Saleh Alessa
  • Patent number: 11969001
    Abstract: The invention relates to a process for producing food ingredients from Stevia rebaudiana plant and their use in food products, beverages and other consumables. Obtained compositions are useful as flavors, sweeteners, antioxidants, and other functional ingredients.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: April 30, 2024
    Assignee: PURECIRCLE USA INC.
    Inventors: Avetik Markosyan, Yeen Yee Wong, Pei Chen Koh
  • Patent number: 11964033
    Abstract: A method of providing a treatment for cleaning and removing oils from hair includes providing a cosmetic that includes a blend of a powder phase including at least two absorbents selected from the group of mica, silica, starch, talc, kaolin and zeolite, and at least one emollient with a solvent phase. The blended powder and solvent phases are formed into a dry shampoo product adapted for manual application to the hair. A porous mold may be used to provide the cosmetic. Techniques may be applied to other forms of cosmetic compositions.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: April 23, 2024
    Assignee: Mana Products, Inc.
    Inventors: George Lambridis, Julio Pina
  • Patent number: 11965178
    Abstract: In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: April 23, 2024
    Assignee: Cellphire, Inc.
    Inventors: Keith Andrew Moskowitz, Rafael Jorda, Ying Yi Zheng, Daniel Allen Sheik